Tirzepatide acts as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, making it an effective treatment of type 2 dia- betes with hypoglycemic and weight-loss effects. Due to their clinical value and pharmacological reliability, GLP-1 receptor agonists occupy a firm position in the global pharmaceutical landscape. Therefore, accurate quality control is essential, especially as the amino acid sequence and higher order structure have a significant impact on the therapeutic performance.
This Application Note outlines a structured method development for the analysis of tirzepatide. The screening protocol evaluates pH and organic modifier in the mobile phase, column temperature, stationary phase chemistry and the impact of bioinert column hardware.
>> Download the Application Note as a PDF
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
